Literature DB >> 24937526

Design and synthesis of hydrolytically stable multivalent ligands bearing thiodigalactoside analogues for peanut lectin and human galectin-3 binding.

Alejandro J Cagnoni1, José Kovensky, María Laura Uhrig.   

Abstract

Herein, we describe the design and synthesis of a novel family of hydrolytically stable glycoclusters bearing thiodigalactoside (TDG) analogues as recognition elements of β-galactoside binding lectins. The TDG analogue was synthesized by thioglycosylation of a 6-S-acetyl-α-D-glucosyl bromide with the isothiouronium salt of 2,3,4,6-tetra-O-acetyl-β-D-galactose. Further propargylation of the TDG analogue allowed the coupling to azido-functionalized oligosaccharide scaffolds through copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) under microwave activation. The final mono-, di-, and tetravalent ligands were resistant to enzymatic hydrolisis by Escherichia coli β-galactosidase. Binding affinities to peanut agglutinin and human galectin-3 were measured by isothermal titration calorimetry which showed K(a) constants in the micromolar range as well as a multivalent effect. Monovalent ligand exhibited a binding affinity higher than that of thiodigalactoside. Docking studies performed with a model ligand on both β-galactoside binding lectins showed additional interactions between the triazole ring and lectin amino acid residues, suggesting a positive effect of this aromatic residue on the biological activity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24937526     DOI: 10.1021/jo500883v

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  8 in total

1.  Multivalent sialylation of β-thio-glycoclusters by Trypanosoma cruzi trans sialidase and analysis by high performance anion exchange chromatography.

Authors:  Rosalía Agustí; María Emilia Cano; Alejandro J Cagnoni; José Kovensky; Rosa M de Lederkremer; María Laura Uhrig
Journal:  Glycoconj J       Date:  2016-06-15       Impact factor: 2.916

Review 2.  Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure.

Authors:  Diego José Laderach; Daniel Compagno
Journal:  Cancers (Basel)       Date:  2021-09-09       Impact factor: 6.575

3.  Effects of linker and liposome anchoring on lactose-functionalized glycomacromolecules as multivalent ligands for binding galectin-3.

Authors:  Tanja Freichel; Dominic Laaf; Miriam Hoffmann; Patrick B Konietzny; Viktoria Heine; Robert Wawrzinek; Christoph Rademacher; Nicole L Snyder; Lothar Elling; Laura Hartmann
Journal:  RSC Adv       Date:  2019-07-29       Impact factor: 4.036

Review 4.  Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer.

Authors:  Alejandro J Cagnoni; Juan M Pérez Sáez; Gabriel A Rabinovich; Karina V Mariño
Journal:  Front Oncol       Date:  2016-05-13       Impact factor: 6.244

5.  Multivalent Lactose-Ferrocene Conjugates Based on Poly (Amido Amine) Dendrimers and Gold Nanoparticles as Electrochemical Probes for Sensing Galectin-3.

Authors:  Manuel C Martos-Maldonado; Indalecio Quesada-Soriano; Luis García-Fuentes; Antonio Vargas-Berenguel
Journal:  Nanomaterials (Basel)       Date:  2020-01-24       Impact factor: 5.076

6.  Synthetic Studies on the Incorporation of N-Acetylallosamine in Hyaluronic Acid-Inspired Thiodisaccharides.

Authors:  Alejandro E Cristófalo; María Laura Uhrig
Journal:  Molecules       Date:  2021-01-01       Impact factor: 4.411

7.  8-Hydroxyquinoline Glycoconjugates Containing Sulfur at the Sugar Anomeric Position-Synthesis and Preliminary Evaluation of Their Cytotoxicity.

Authors:  Monika Krawczyk; Gabriela Pastuch-Gawołek; Agnieszka Hadasik; Karol Erfurt
Journal:  Molecules       Date:  2020-09-11       Impact factor: 4.411

8.  Probing Site-Selective Conjugation Chemistries for the Construction of Homogeneous Synthetic Glycodendriproteins.

Authors:  Isidro Cobo; M Isabel Matheu; Sergio Castillón; Benjamin G Davis; Omar Boutureira
Journal:  Chembiochem       Date:  2022-04-01       Impact factor: 3.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.